As of 2025-09-15, the EV/EBITDA ratio of Enanta Pharmaceuticals Inc (ENTA) is -1.44. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ENTA's latest enterprise value is 133.56 mil USD. ENTA's TTM EBITDA according to its financial statements is -93.04 mil USD. Dividing these 2 quantities gives us the above ENTA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 14.0x | 10.8x |
| Forward P/E multiples | 10.2x - 17.1x | 12.6x |
| Fair Price | (42.35) - (58.89) | (48.66) |
| Upside | -611.5% - -811.2% | -687.7% |
| Date | EV/EBITDA |
| 2025-09-12 | -1.44 |
| 2025-09-11 | -1.52 |
| 2025-09-10 | -1.45 |
| 2025-09-09 | -1.61 |
| 2025-09-08 | -1.58 |
| 2025-09-05 | -1.57 |
| 2025-09-04 | -1.58 |
| 2025-09-03 | -1.56 |
| 2025-09-02 | -1.60 |
| 2025-08-29 | -1.46 |
| 2025-08-28 | -1.53 |
| 2025-08-27 | -1.49 |
| 2025-08-26 | -1.52 |
| 2025-08-25 | -1.52 |
| 2025-08-22 | -1.56 |
| 2025-08-21 | -1.51 |
| 2025-08-20 | -1.56 |
| 2025-08-19 | -1.46 |
| 2025-08-18 | -1.41 |
| 2025-08-15 | -1.37 |
| 2025-08-14 | -1.31 |
| 2025-08-13 | -1.27 |
| 2025-08-12 | -1.11 |
| 2025-08-11 | -1.02 |
| 2025-08-08 | -1.12 |
| 2025-08-07 | -1.14 |
| 2025-08-06 | -1.17 |
| 2025-08-05 | -1.24 |
| 2025-08-04 | -1.16 |
| 2025-08-01 | -1.17 |
| 2025-07-31 | -1.27 |
| 2025-07-30 | -1.28 |
| 2025-07-29 | -1.39 |
| 2025-07-28 | -1.38 |
| 2025-07-25 | -1.23 |
| 2025-07-24 | -1.22 |
| 2025-07-23 | -1.31 |
| 2025-07-22 | -1.30 |
| 2025-07-21 | -1.31 |
| 2025-07-18 | -1.27 |
| 2025-07-17 | -1.19 |
| 2025-07-16 | -1.16 |
| 2025-07-15 | -1.05 |
| 2025-07-14 | -1.13 |
| 2025-07-11 | -1.04 |
| 2025-07-10 | -1.14 |
| 2025-07-09 | -1.17 |
| 2025-07-08 | -1.31 |
| 2025-07-07 | -1.29 |
| 2025-07-03 | -1.35 |